Im­muno­Gen’s ovar­i­an can­cer come­back not as rosy as ex­pect­ed as pro­gres­sion-free sur­vival lags

Back in No­vem­ber, Im­muno­Gen ral­lied in­vestors with what looked like a come-from-be­hind Phase III win. But this morn­ing, the biotech was back to play­ing de­fense af­ter dis­ap­point­ing an­a­lysts with the de­tails.

Im­muno­Gen’s sec­ond shot at get­ting mirve­tux­imab so­rav­tan­sine across the fin­ish line be­came a lit­tle hazier this week­end. In­vestors want­ed more than 5 months of pro­gres­sion-free sur­vival, but mirve­tux­imab could on­ly de­liv­er 4.3 months in the SO­RAYA tri­al of pa­tients with a cer­tain ovar­i­an can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER